Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terminalia chebula is a plant species whose dried fruit is widely used in traditional medicine systems such as Ayurveda, Unani, Tibetan, and Siddha, often referred to as “Haritaki” or “King of Medicine”. It is prized for its **antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and neuroprotective effects**, with traditional indications including constipation, digestive complaints, liver health, aging, diabetes, high cholesterol, and neurological conditions such as mild cognitive impairment. Modern studies confirm a broad range of pharmacological activities, including inhibition of acetylcholinesterase and butyrylcholinesterase, scavenging free radicals, reducing inflammation, modulating apoptosis, and antagonism of NMDA receptors. The main active constituents are chebulagic acid, chebulinic acid, chebulaginic acid, gallic acid, ellagic acid, and tannins, which contribute to its biological effects. Terminalia chebula is typically consumed orally as powder, extract, or decoction, and has a strong ethnomedical history but is not recognized as a pharmaceutical drug in modern regulatory frameworks[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on terminalia chebula.